Hinova Pharmaceuticals Inc. A (SHG:688302) — Stock Price
Hinova Pharmaceuticals Inc. A (SHG:688302) is currently trading at CN¥37.56 CNY, up 0.97% today. Over the past 52 weeks, shares have ranged between CN¥31.98 and CN¥67.20. This page tracks Hinova Pharmaceuticals Inc. A's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Hinova Pharmaceuticals Inc. A (688302) total market value.
Hinova Pharmaceuticals Inc. A (688302) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hinova Pharmaceuticals Inc. A's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hinova Pharmaceuticals Inc. A Income Statement — Revenue, Profit & Earnings by Year
Hinova Pharmaceuticals Inc. A's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | CN¥366.84K | CN¥0.00 | CN¥1.65 Million | CN¥0.00 | CN¥0.00 |
| Cost of Revenue | CN¥335.92K | — | CN¥766.47K | — | — |
| Gross Profit | CN¥30.92K | CN¥0.00 | CN¥884.36K | CN¥0.00 | CN¥0.00 |
| Research & Development | CN¥174.03 Million | CN¥248.27 Million | CN¥251.37 Million | CN¥264.93 Million | CN¥428.93 Million |
| SG&A | CN¥25.78 Million | CN¥65.56 Million | CN¥78.72 Million | CN¥66.70 Million | CN¥53.84 Million |
| Total Operating Expenses | CN¥223.36 Million | CN¥330.64 Million | CN¥339.35 Million | CN¥326.84 Million | CN¥481.49 Million |
| Operating Income | CN¥-223.00 Million | CN¥-330.64 Million | CN¥-337.70 Million | CN¥-326.84 Million | CN¥-481.49 Million |
| EBITDA | — | — | CN¥-292.12 Million | CN¥-302.64 Million | CN¥-489.18 Million |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥526.61K | CN¥1.49 Million | CN¥3.92 Million | CN¥2.56 Million | CN¥361.77K |
| Income Before Tax | CN¥-199.48 Million | CN¥-294.14 Million | CN¥-301.51 Million | CN¥-306.18 Million | CN¥-489.85 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥-199.50 Million | CN¥-294.16 Million | CN¥-301.51 Million | CN¥-306.18 Million | CN¥-489.85 Million |
Hinova Pharmaceuticals Inc. A Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hinova Pharmaceuticals Inc. A's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | CN¥1.36 Billion | CN¥1.49 Billion | CN¥1.74 Billion | CN¥982.35 Million | CN¥1.19 Billion |
| Total Current Assets | CN¥885.54 Million | CN¥1.15 Billion | CN¥1.61 Billion | CN¥955.24 Million | CN¥1.18 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥210.49 Million | CN¥290.62 Million | CN¥366.24 Million | — | — |
| Net Receivables | — | — | — | — | — |
| Inventory | CN¥4.56K | CN¥5.58K | CN¥6.48K | CN¥4.92K | CN¥4.52K |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥169.33 Million | CN¥124.47 Million | CN¥149.68 Million | CN¥193.59 Million | CN¥202.33 Million |
| Total Current Liabilities | CN¥146.95 Million | CN¥106.84 Million | CN¥138.27 Million | CN¥191.33 Million | CN¥199.52 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | CN¥1.19 Billion | CN¥1.37 Billion | CN¥1.59 Billion | CN¥788.76 Million | CN¥986.15 Million |
| Retained Earnings | CN¥-1.49 Billion | CN¥-1.29 Billion | CN¥-996.06 Million | CN¥-694.54 Million | CN¥-388.36 Million |
Hinova Pharmaceuticals Inc. A Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hinova Pharmaceuticals Inc. A generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥-187.08 Million | CN¥-255.51 Million | CN¥-314.92 Million | CN¥-227.82 Million | CN¥-243.66 Million |
| Capital Expenditures | CN¥89.55 Million | CN¥99.18 Million | CN¥69.21 Million | CN¥19.77 Million | CN¥2.50 Million |
| Free Cash Flow | CN¥-276.63 Million | CN¥-354.68 Million | CN¥-384.13 Million | CN¥-247.60 Million | CN¥-246.16 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | CN¥904.00K | CN¥3.92 Million | CN¥2.56 Million | CN¥361.17K |
| Stock-Based Compensation | — | — | — | CN¥108.82 Million | CN¥91.61 Million |
| Depreciation | CN¥5.97 Million | CN¥6.42 Million | CN¥5.47 Million | CN¥3.05 Million | CN¥1.20 Million |
| Change in Cash | CN¥-219.96 Million | CN¥-388.38 Million | CN¥300.38 Million | CN¥-234.87 Million | CN¥1.12 Billion |
Hinova Pharmaceuticals Inc. A Earnings History — EPS Actual vs. Analyst Estimates
Track Hinova Pharmaceuticals Inc. A's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 25, 2025 | — | — | — |
| Apr 27, 2023 | -0.76 | — | — |
| Feb 27, 2023 | -0.80 | — | — |
| Oct 27, 2022 | -0.75 | — | — |
| Aug 30, 2022 | -0.62 | — | — |